Boosting Endocannabinoid Levels Restored Motor Learning in Huntington's Disease Mice | Research

The takeaway

Oral administration of a drug that prevents 2-AG breakdown increased striatal endocannabinoid levels, restored corticostriatal synaptic plasticity, and eliminated the motor learning deficit in a Huntington's disease mouse model.

Huntington's disease researchers, neurologists, and those interested in endocannabinoid-based therapeutics for neurodegeneration.

What the researchers found

Three weeks of oral JZL184 (a 2-AG degradation inhibitor) significantly increased 2-AG levels in striatal tissue. Treatment eliminated the difference in rotarod motor learning between Huntington's (YAC128) and wild-type mice and normalized high-frequency stimulation-induced striatal plasticity to wild-type levels. No effects on open field behavior were observed.

Why it matters

Huntington's disease has no disease-modifying treatment. This study shows that boosting the brain's own endocannabinoid system can correct the specific synaptic plasticity deficits that underlie early motor symptoms, offering a potential new therapeutic target.

The numbers in context

3-week oral JZL184 treatment. Significant increase in striatal 2-AG levels. Rotarod motor learning deficit eliminated (YAC128 normalized to WT levels). High-frequency stimulation-induced striatal plasticity normalized. No effect on open field behavior.

How the study worked

JZL184 administered orally over 3 weeks to YAC128 Huntington's disease model mice and wild-type littermates. Motor function assessed via rotarod, open field, and other behavioral tasks. Brain tissue analyzed for endocannabinoid levels. Corticostriatal synaptic plasticity measured via electrophysiology in brain slices.

What this study cannot tell us

YAC128 mouse model does not fully replicate human Huntington's disease. Only early-stage motor symptoms were studied; effects on later neurodegeneration unknown. JZL184 is a research tool, not a clinical drug. Three-week treatment is short relative to the chronic nature of HD. Only open field and rotarod were used for behavioral assessment.

How to read the evidence

Well-designed preclinical study with behavioral, biochemical, and electrophysiological outcomes, but mouse model and short treatment duration limit translation.

When this study was published

Published 2025.

The bigger picture

The endocannabinoid system is increasingly recognized as a target in neurodegenerative diseases. This study provides preclinical justification for clinical trials of therapies that boost 2-AG signaling in Huntington's patients, potentially addressing early motor symptoms before irreversible neurodegeneration occurs.

Questions still open

Whether 2-AG augmentation would also slow neurodegeneration in addition to improving motor function
Whether clinical-stage MAGL inhibitors could be tested in Huntington's patients

Common questions

Could cannabis treat Huntington's disease?

This study did not use cannabis; it used a specific drug (JZL184) that boosts the brain's own endocannabinoid (2-AG) levels. While the endocannabinoid system is involved, smoking or ingesting cannabis would have different and less targeted effects than the approach studied here.

What is corticostriatal synaptic plasticity?

It is the ability of connections between the cortex and striatum to strengthen or weaken in response to activity. This plasticity is essential for motor learning and is disrupted early in Huntington's disease. Restoring it with endocannabinoid augmentation is the key finding of this study.

Read the original research

Upregulation of endocannabinoid signaling in vivo restores striatal synaptic plasticity and motor performance in Huntington's disease mice.

Journal of Huntington's disease, 14(2), 149-161

View on PubMed ↗Publisher’s paper ↗

Citation

Sepers, Marja D; Woodard, Cameron L; Ramandi, Daniel; Vecchiarelli, Haley A; Hill, Matthew N; Raymond, Lynn A. (2025). Upregulation of endocannabinoid signaling in vivo restores striatal synaptic plasticity and motor performance in Huntington's disease mice.. Journal of Huntington's disease, 14(2), 149-161. https://doi.org/10.1177/18796397251337021